Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 14, 2026, 12:08 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1681–1704 of 6,233 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Part 1 Clear all

Conditions: Diabetes Mellitus, Type 2
Interventions: Food support, Case-management; Other
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years and older
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: Martinez, California

Conditions: Recurrent Pericarditis
Interventions: KPL-914; Drug
Lead sponsor: Kiniksa Pharmaceuticals (UK), Ltd.; Industry
Eligibility: 6 Years to 75 Years
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 14
States / cities: Washington D.C., District of Columbia • DeLand, Florida • Jacksonville, Florida + 11 more

Conditions: Neoplasms
Interventions: VIP152 (BAY 1251152), VIP152 (BAY 1251152) 30 mg, Keytruda, VIP152 (BAY 1251152) 15 mg; Drug
Lead sponsor: Vincerx Pharma, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 110 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2024
U.S. locations: 13
States / cities: Springdale, Arkansas • Louisville, Kentucky • Silver Spring, Maryland + 10 more

Conditions: Parenting
Interventions: Home Safety Hero Computer Game; Behavioral
Lead sponsor: Penn State University; Other
Eligibility: 12 Years to 20 Years
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2022
U.S. locations: 1
States / cities: University Park, Pennsylvania

Conditions: Autoimmune Diseases, Ulcerative Colitis, Multiple Sclerosis, Scleroderma, Ankylosing Spondylitis, Celiac Disease, Non-radiographic Axial Spondyloarthritis (Nr-axSpA), Crohn&Amp;#39;s Disease, Birdshot Chorioretinitis
Interventions: Companion blood samples with procedure; Procedure
Lead sponsor: TScan Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 238 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 11
States / cities: Orange, California • Sherman Oaks, California • Skokie, Illinois + 7 more

Conditions: Systemic Lupus Erythematosus, Rheumatoid Arthritis
Interventions: PF-06835375, Placebo; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 74 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2022
U.S. locations: 17
States / cities: Anniston, Alabama • Beverly Hills, California • Los Angeles, California + 9 more

Conditions: Epilepsy
Interventions: radiosurgery, temporal lobectomy; Procedure
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years and older
Enrollment: 61 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2016
U.S. locations: 13
States / cities: Birmingham, Alabama • La Jolla, California • Los Angeles, California + 10 more

Conditions: Head Cancer Neck
Interventions: PET/MRI with FDG, MRI scan without contrast, MRI with gadolinium; Radiation
Lead sponsor: NYU Langone Health; Other
Eligibility: 18 Years and older
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2026
U.S. locations: 2
States / cities: New York, New York

Conditions: Breast Cancer
Interventions: Neratinib, Fulvestrant; Drug
Lead sponsor: Dana-Farber Cancer Institute; Other
Eligibility: 18 Years and older · Female only
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2021
U.S. locations: 6
States / cities: Indianapolis, Indiana • Brewer, Maine • Boston, Massachusetts + 3 more

Conditions: Multiple Myeloma
Interventions: Ruxolitinib Oral Tablet [Jakafi], Lenalidomide, Methylprednisolone; Drug
Lead sponsor: Oncotherapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 134 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2027
U.S. locations: 13
States / cities: Alhambra, California • Bakersfield, California • Encinitas, California + 9 more

Conditions: Advanced Solid Tumor, Clear Cell Renal Cell Carcinoma, Hepatocellular Carcinoma, Non-small Cell Lung Cancer
Interventions: CHS-388, Pembrolizumab, Toripalimab; Drug
Lead sponsor: Coherus Oncology, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 145 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2025
U.S. locations: 18
States / cities: Duarte, California • Los Angeles, California • San Francisco, California + 15 more

Conditions: Major Depressive Disorder
Interventions: No intervention will be administered as part of this study.; Other
Lead sponsor: Usona Institute; Other
Eligibility: 21 Years to 65 Years
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 1
States / cities: Lauderhill, Florida

Conditions: Healthy Volunteer
Interventions: PF-06882961 followed by PF-06882961/PF-06865571, PF-06882961/PF-06865571 followed by PF-06882961, PF-06882961 + PF-06865571; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 27 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021
U.S. locations: 1
States / cities: Tustin, California

Conditions: Medulloblastoma, Central Nervous System Embryonal Tumors
Interventions: Induction, Single Cycle Intensive Chemotherapy, Tandem 3 Cycle Intensive Chemotherapy; Drug
Lead sponsor: Parth Patel; Other
Eligibility: Up to 10 Years
Enrollment: 250 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2030
U.S. locations: 55
States / cities: Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 47 more

Conditions: Prostatic Neoplasms
Interventions: JNJ-75229414, Bridging Therapy; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2026
U.S. locations: 8
States / cities: Duarte, California • Louisville, Kentucky • Minneapolis, Minnesota + 4 more

Conditions: Healthy
Interventions: PF-04308515, Placebo, PF-04308515 Tablet; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 58 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Rett Syndrome
Interventions: TSHA-102; Genetic
Lead sponsor: Taysha Gene Therapies, Inc.; Industry
Eligibility: 6 Years to 21 Years · Female only
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2031
U.S. locations: 8
States / cities: Duarte, California • La Jolla, California • Oakland, California + 5 more

Conditions: Healthy Participants
Interventions: AZD5462, Placebo; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 98 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Glendale, California

Conditions: Childhood Hematopoietic and Lymphatic System Neoplasm, Childhood Malignant Solid Neoplasm
Interventions: Non-Interventional Study; Other
Lead sponsor: Children's Oncology Group; Network
Eligibility: 18 Years and older
Enrollment: 2,425 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2031
U.S. locations: 28
States / cities: Birmingham, Alabama • Little Rock, Arkansas • Oakland, California + 25 more

Conditions: Tobacco-Related Carcinoma, Smoking Cessation
Interventions: Smoking cessation education, Survey Administration, Telephone-Based Intervention, Urine Specimen Collection, Silicone Wrist Band, Interview, Focus Group; Other · Behavioral · Procedure
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years and older
Enrollment: 760 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Healthy Subjects, Hepatic Impairment, Infection, Human Immunodeficiency Virus, HIV Infections
Interventions: GSK1349572; Drug
Lead sponsor: ViiV Healthcare; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 16 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2011
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Multiple Myeloma
Interventions: Etentamig, Lenalidomide, Dexamethasone, Daratumumab, Carfilzomib, Mezigdomide, Iberdomide, ABBV-2001, Pomalidomide; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years and older
Enrollment: 602 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2036
U.S. locations: 15
States / cities: Duarte, California • Irvine, California • San Francisco, California + 11 more

Conditions: Solid Tumor
Interventions: Farletuzumab ecteribulin, Prednisone, Prednisolone, Dexamethasone, Lenvatinib; Drug
Lead sponsor: Eisai Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 182 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2030
U.S. locations: 24
States / cities: Tucson, Arizona • Little Rock, Arkansas • Palo Alto, California + 19 more

Conditions: Type II Diabetes Mellitus, Obesity
Interventions: Gastric Band, Gastric Sleeve, Gastrostomy Tube; Procedure
Lead sponsor: East Carolina University; Other
Eligibility: 18 Years to 60 Years · Female only
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2012
U.S. locations: 1
States / cities: Greenville, North Carolina

Search by objective public record fields.

Pilot Trial of the Nutrition-Supported Diabetes Education Program

A Pilot Study of KPL-914 in Recurrent Pericarditis

Phase I Dose Escalation Study for VIP152 in Patients With Advanced Cancer

Developing an Injury Prevention Simulation Game to Better Engage Parents in Services -Home Safety Hero

A Biospecimen Collection Study to Identify the Targets of Disease-Reactive T Cells in Patients With Autoimmune Disease

Safety and Tolerability Study Of PF-06835375 In Subjects With Seropositive Systemic Lupus Erythematosus Or Rheumatoid Arthritis

Radiosurgery or Open Surgery for Epilepsy Trial

Diffusion MRI for Head and Neck Cancer

Neratinib +/- Fulvestrant in HER2+, ER+ Metastatic Breast Cancer

A Phase 1 Study of Ruxolitinib, Steroids and Lenalidomide for Relapsed/Refractory Multiple Myeloma (RRMM) Patients

Study of CHS-388 (Formerly Known as SRF388) in Patients With Advanced Solid Tumors

PSIL201 Long-term Follow-up Study: Psilocybin or Niacin / Major Depressive Disorder

A Drug-Drug Interaction Study Between PF-06882961 and PF-06865571 in Healthy Adult Participants and Overweight Adults or Adults With Obesity Who Are Otherwise Healthy

HeadStart4: Newly Diagnosed Children (<10 y/o) With Medulloblastoma and Other CNS Embryonal Tumors

A Study of JNJ-75229414 for Metastatic Castration-resistant Prostate Cancer Participants

Multiple Dose Escalation Trial Of PF-04308515 In Healthy Volunteers

A Phase 1/2/3 Study of TSHA-102 Gene Therapy in Females With Rett Syndrome (REVEAL Pivotal Study)

A Study to Assess the Safety, Tolerability, and Pharmacokinetics of AZD5462 Following Single and Multiple Ascending Dose Administration to Healthy Volunteers

Quality of End-of-Life Care for Children With Cancer

Healthy Family Project: Tobacco Use and Smoke Exposure in Asian American Communities

GSK1349572 Hepatic Impairment Study

A Study to Assess Change in Disease Activity and Adverse Events (AE)s in Adult Participants With Multiple Myeloma Receiving T Cell Engaging Bi/Tri-specific Antibodies Intravenously (IV)/Subcutaneously (SC) Alone or in Combinations

A Study to Evaluate the Safety, Tolerability, and Efficacy of MORAb-202 (Herein Referred to as Farletuzumab Ecteribulin), a Folate Receptor Alpha (FRα)-Targeting Antibody-drug Conjugate (ADC) in Participants With Selected Tumor Types

Metabolomics of Roux-en-Y Gastric Bypass (RYGB) With Gastrostomy